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BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors
elicit a transient anti-tumor response in ∼80% of BRAFV600-mutant
melanoma patients that almost uniformly precedes the emergence
of resistance. Here we used a mouse model of melanoma in which
melanocyte-specific expression of BrafV618E (analogous to the hu-
man BRAFV600E mutation) led to the development of skin hyper-
pigmentation and nevi, as well as melanoma formation with
incomplete penetrance. Sleeping Beauty insertional mutagenesis
in this model led to accelerated and fully penetrant melanomagenesis
and synchronous tumor formation. Treatment of BrafV618E trans-
poson mice with the BRAF inhibitor PLX4720 resulted in tumor
regression followed by relapse. Analysis of transposon insertions
identified eight genes including Braf, Mitf, and ERas (ES-cell
expressed Ras) as candidate resistance genes. Expression of ERAS
in human melanoma cell lines conferred resistance to PLX4720
and induced hyperphosphorylation of AKT (v-akt murine thy-
moma viral oncogene homolog 1), a phenotype reverted by com-
binatorial treatment with PLX4720 and the AKT inhibitor MK2206.
We show that ERAS expression elicits a prosurvival signal associ-
ated with phosphorylation/inactivation of BAD, and that the re-
sistance of hepatocyte growth factor-treated human melanoma
cells to PLX4720 can be reverted by treatment with the BAD-like
BH3 mimetic ABT-737. Thus, we define a role for the AKT/BAD
pathway in resistance to BRAF inhibition and illustrate an in vivo
approach for finding drug resistance genes.
melanoma | drug resistance | BRAF inhibitors | mouse models
The discovery that ∼50–60% of melanomas carry BRAF
V600E
point mutations (1) prompted the generation of compounds
specifically targeting this hyperactive mutated kinase. One such
compound, PLX4032, has shown unprecedented therapeutic effi-
cacy in clinical trials and was therefore FDA-approved for clinical
therapy under the name vemurafenib. Despite its remarkable ef-
ficacy, almost all patients receiving BRAF inhibitor treatment re-
lapsed after weeks to months of therapy (2–5). Acquired resistance
to BRAF inhibitors has since been a major focus of research
and two major paths to resistance have emerged: MAPK-dependent
and MAPK-independent mechanisms. MAPK-dependent mecha-
nisms primarily involve reactivation of the MAPK pathway to
substitute for the inhibition of BRAFV600E. This may be achieved
through mechanisms including expression of alternative splicing
forms of BRAFV600E, amplification of BRAFV600E, the acquisition of
activating mutations in NRAS or MEK (MAP2K1), or loss of NF1.
Similarly, COT (MAP3K8) overexpression has been shown to drive
resistance through ERK activation independent of RAF signaling
(6–11). Elevated signaling through the PI3K/AKT pathway, with or
without concomitant MAPK reactivation, represents an alternative
path to resistance. Indeed, AKT signaling mediated by several ge-
netic lesions including increased expression of the insulin-like growth
factor 1 receptor (IGF1R) and expression of hepatocyte growth
factor (HGF) by stromal cells has been linked to BRAF inhibitor
resistance (12–14). Similarly, activation of the PI3K pathway
through loss of PTEN, or deregulation of other genes (e.g., AKT3,
BCL2A1, IGF1, and PIB5PA), has been shown to result in re-
sistance to BRAF inhibitor-induced apoptosis (15–19). Additional
mediators of resistance have also been proposed, including up-
regulation of the tyrosine kinase platelet-derived growth factor re-
ceptor beta (PDGFRB), possibly through MAPK- or PI3K-related
mechanisms (8).
We generated a mouse model of BrafV618E-induced mela-
noma (analogous to BRAFV600E in humans; transcript
ENSMUSE00000277767 in mouse) and used it in combination
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with Sleeping Beauty insertional mutagenesis to identify mecha-
nisms of resistance to BRAF inhibition using PLX4720, a vemur-
afenib analog. As in patients with tumors carrying BRAFV600
mutations, melanomas in our mouse model showed an initial re-
sponse to BRAF inhibitor treatment, characterized by rapid tumor
regression, followed by tumor recurrence after weeks to months
of therapy. Analysis of transposon insertion sites in naïve and
PLX4720-resistant melanomas identified the proto-oncogene
ERas, and seven other genes, as putative mediators of resistance.
We show that ERAS expression confers resistance associated with
inactivation of the proapoptotic protein BAD in an AKT/PI3K-
dependent manner, and that BAD also contributes to BRAF
inhibitor resistance in the context of activated HGF signaling.
These data illustrate the human relevance of genes/pathways
found through insertional mutagenesis screens for drug re-
sistance mediators.
Results
Targeted Expression of Oncogenic BrafV618E Induces Skin Hyper-
pigmentation, Nevi, and Melanoma. We targeted the endogenous
murine Braf locus by introducing a stop element (LoxP-Stop-
LoxP or LSL cassette) into intron 2 and a V618E mutation into
exon 15 (Fig. 1A). Our model is similar to other models (20, 21)
with the exception of FRT sites in introns 2 and 14 to allow Flp-
mediated conditional deletion of the mutant Braf allele (SI
Materials and Methods and Fig. S1). Validation of the allele is
shown in the SI Materials and Methods.
To target expression of the Braf oncogene specifically to
melanocytes we intercrossed LSL-BrafV618E mice with the me-
lanocyte-specific, 4-hydroxytamoxifen (4-OHT)-inducible Tyros-
inase-CreERT2 allele (TyrCreERT2) (Fig. 1A) (22). Experiments
were performed in LSL-BrafV618E; TyrCreERT2 heterozygotes
owing to perinatal lethality of LSL-BrafV618E homozygotes (23).
To assess the biological effect of BrafV618E activation on the
melanocyte compartment, 3- to 4-wk-old LSL-BrafV618E/+; Tyr-
CreERT2 mice (hereby designated as BC mice) were shaved and
their back skin, flanks, ears, and tail were treated topically with
a 25 mg/mL solution of 4-OHT for two consecutive days. After
∼6–8 wk hyperpigmentation of treated areas and to a lesser ex-
tent all skin surfaces including the urogenital area and paws was
observed, the latter being due to systemic spread of 4-OHT (Fig.
S2A). Histological analysis of back and ear skin revealed a vast
expansion of terminally differentiated, heavily pigmented mela-
nocytes in BC mice treated with 4-OHT, but not in 4-OHT–
treated controls (Brafwt; TyrCreERT2 mice) (Fig. S2 A and C).
One to two months after treatment numerous heavily pig-
mented nevi, primarily located on the trunk skin, were observed
in 4-OHT–treated BC mice (Fig. S2B). Smaller melanocytic nevi
showed melanin-producing cells that were primarily located in
the dermis; some were scattered in the s.c. fat (Fig. S2C). Larger
nevi showed collections of melanin-producing cells in the dermis,
with these collections extending into the fat below (Fig. S2D).
Furthermore, epithelioid blue nevi were infrequently observed,
as previously reported (Fig. S2E) (21). These results are in
keeping with the presence of BRAF mutations in up to 85% of
melanocytic nevi in humans (24, 25).
Progression of melanocytic nevi to malignant melanoma is
rare in humans, yet around 30–50% of melanomas develop from
these benign tumors. Thus, we aged 4-OHT–treated BC mice to
assess the penetrance of spontaneous tumor formation in our
model. We observed that 87% of BC mice developed melanoma,
primarily on the trunk and to a lesser extent on the extremities
(Fig. S2F), similar to previous reports in analogous models (20,
21). The median latency of tumor formation was 426 d (Fig. 1B,
green line) and the average multiplicity of tumor formation was
1. Given that each mouse was covered with hundreds to thou-
sands of nevi, akin to atypical mole syndrome in humans, the
transformation of melanocytic nevi to melanoma is exceedingly
rare and suggests a requirement for additional genetic alter-
ations for melanomagenesis. Those melanomas that did form
were generally hypopigmented and primarily dermal (Fig. S2G).
There was little or no epidermal involvement, and most tumors
had a spindle-cell morphology. Tumors with predominant epi-
thelioid cell features were rarely observed. Melanoma cells dis-
played characteristic enlarged and pleomorphic nuclei, sometimes
with prominent eosinophilic atypical nucleoli and numerous mi-
totic figures (Fig. S2H). Larger lesions showed superficial ulcer-
ation, but with no or very little evidence of an intraepidermal
invasive component (radial/horizontal growth phase) (Fig. S2I).
Infiltration of melanoma cells through the underlying skeletal
muscle and into s.c. adipose tissue was commonly observed (Fig.
S2J). Occasionally melanomas showed foci of lymphocyte aggre-
gates and scattered tumor-infiltrating lymphocytes (Fig. S2K).
Residual pigmented melanocytes were observed in a subset of
melanomas (Fig. S2L). Despite their predominantly amelanotic
nature, tumors expressed the melanocyte lineage markers S100A
and MITF (Fig. S2 M and N). At necropsy draining lymph
nodes appeared brown in color and histological analysis
revealed the presence of lightly pigmented as well as unpig-
mented melanoma cells with pleomorphic nuclei and also
melanophages, which were heavily pigmented owing to phagocy-
tosis of melanin (Fig. S2O and P). Thus, oncogenic BrafV618E alone
is sufficient to initiate melanomagenesis but with incomplete pen-
etrance and with an extended latency, suggesting a requirement for
additional genetic events.
Sleeping Beauty Insertional Mutagenesis Identifies Drivers of Melanoma
Formation and Mediators of Resistance to the BRAF Inhibitor PLX4720.
To identify novel genes and pathways contributing to melanoma
formation and to BRAF inhibitor resistance we performed a for-
ward genetic screen using the Sleeping Beauty (SB) transposon
system (26–28). BC mice were crossed with animals carrying ele-
ments of the SB transposon system to generate quadruple mutant
BCTSB13 animals (LSL-BrafV618E/+; Tyrosinase-CreERT2; T2/Onc;
Rosa26-LSL-SB13; Fig.1A) and triple mutant BCT littermate con-
trols (LSL-BrafV618E/+; Tyrosinase-CreERT2; T2/Onc). Application of
4-OHT to the skin of BCTSB13 mice simultaneously induced ex-
pression of the BrafV618Emutant allele and transposon mobilization,
with consequent induction of additional random somatic mutations
(Fig. 1A). Insertional mutagenesis in BCTSB13 mice led to a dra-
matic acceleration of melanoma formation and a decrease in the
median survival to ∼130 d (P < 0.0001) compared with BC or BCT
mice, whose median survival was comparable (426 and 408.5 d,
respectively) (Fig. 1B). Importantly, transposon activation in mel-
anocytes not only accelerated tumorigenesis but also increased tu-
mor multiplicity to an average of 3.6 tumors per mouse, with a few
mice developing more than 10 synchronous melanomas (Fig. 1C).
From a cohort of 78 BCTSB13 mice we collected 278 tumors for
transposon insertion site analysis.
In parallel with the abovementioned study we randomly en-
rolled a cohort of 4-OHT–treated BCTSB13 mice for treatment
with the BRAF inhibitor PLX4720 (29). Mice with melanomas of
at least 200 mm3 in size were transferred onto a standard labo-
ratory diet containing PLX4720. An acute response to PLX4720
treatment was evident; melanomas initially regressed during the
first 1–4 wk of treatment (Fig. 1D). Stable disease was main-
tained in BCTSB13 mice for an average of 76 d (Fig. 1 D and E)
until relapse at the site of the initial tumor formation was ob-
served. After relapse tumors were collected before reaching 10%
of body weight. We harvested 53 PLX4720-resistant tumors from
30 mice from which we isolated genomic DNA for insertion site
analysis. Importantly, comparison of PLX4720 levels by mass
spectrometry of plasma, tissues (liver, spleen, skin, and salivary
gland), and tumor material in mice carrying tumors either re-
sistant or sensitive to PLX4720 revealed comparable concen-
trations of PLX4720 ranging from 200 μM in plasma to 70 μM in
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Fig. 1. Sleeping Beauty insertional mutagenesis accelerates BrafV618E-induced melanoma development and induces resistance to PLX4720. (A) Scheme of the
alleles in the LSL-BrafV618E/+; Tyrosinase-CreERT2 (or BC) and LSL-BrafV618E/+; Tyrosinase-CreERT2; T2/Onc; Rosa26-LSL-SB13 (or BCTSB13) mouse models. Application
of 4-OHT onto the skin of these mice activates CreERT2 selectively in melanocytes, inducing the simultaneous expression of both oncogenic BrafV618E and SB13
transposase. The T2/Onc transposon contains elements to elicit transcriptional activation such as the MSCV 5′ LTR and splice donor (SD), or inactivation such as
splice acceptors (SA) and polyadenylation signals (pA). The position of LoxP sites (black arrowheads) and FRT sites (white arrowheads) are indicated. (B)
Kaplan–Meier survival curve of 4-OHT–treated mice showing that BCTSB13 mice (n = 84) have a reduced median survival compared with BC mice (n = 16; median
survival 131 vs. 426 d, P < 0.0001), BCT mice (n = 10; median survival 131 vs. 382 d, P < 0.0001), and control mice (BTSB13 and CTSB13 mice; n = 35; median survival
>600 d, P < 0.0001). (C) Number of tumors developed in the cohort of 4-OHT–treated BCTSB13 mice; 70% of the mice developed more than one tumor. (D)
Melanomas of 4-OHT–treated BCTSB13 mice first respond to PLX4720 and shrink but then relapse upon continuous, prolonged treatment. After appearance,
tumor sizes were measured twice a week before and after the beginning of treatment with a PLX4720-containing diet (represented by the dotted line). Tumor
volumes were calculated as described in Materials and Methods. Each mouse was placed on drug treatment once it had developed at least one melanoma of
200 mm3. Mice were then continuously fed with the drug-containing diet until the endpoint. (E) Photographs showing BCTSB13 mouse melanomas before
treatment (Left), at completed shrinkage (Center) and upon relapse (Right). The indicated days represent the duration of drug treatment.
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the tumors and 6–30 μM in the other tissues (Fig. S3). This
suggests that drug efflux does not contribute significantly to
PLX4720 resistance in our model.
Furthermore, to rule out the possibility that drug resistance is
due to mechanisms not mediated by transposon insertion events
we performed whole-exome sequencing of six BCTSB13-resistant
tumors, revealing no acquired point mutations in established
resistance drivers Braf, Nras, Cot, Pdgfrb, Raf1, Cdkn2a, Nf1,
Igf1r, Mek1, Mek2 (Map2k2), Pten, or Met (European Nucleotide
Archive accession no. ERP002600).
Genomic DNA from PLX4720-naïve and -resistant melanoma
samples were subjected to splinkerette PCR and 454 sequencing
to isolate common insertion sites (CISs), which were defined
using Gaussian kernel convolution statistics (GKC) (30). The list
of candidate drivers identified in BCTSB13 melanomas
(PLX4720-naïve) (Dataset S1) included 56 statistically signifi-
cant loci (P < 0.05; Materials and Methods) and many well-
established melanoma driver genes including Cdkn2a and Pten
(20, 21, 31–33), as well as candidate drivers such as Atrx and
Sox6, which have not previously been described in melanoma.
The patterns of T2/Onc transposon insertions in Cdkn2a and
Pten (Fig. S4 A and B) were in keeping with the known biological
roles for these genes in melanoma development. Furthermore,
CISs also identified competitive endogenous RNAs of Pten such
as Zeb2 (34). Importantly, hierarchical clustering revealed that
tumors collected from the same mouse were genetically in-
dependent (Fig. S4C).
The analysis of insertion sites from the 53 PLX4720-resistant
melanomas identified 10 CISs (P < 0.05) (Fig. 2 and Dataset S1).
We performed a Fisher’s exact statistical test to compare the CIS
insertions found in the PLX4720-naïve and PLX4720-resistant
tumors in an attempt to identify significantly enriched loci fol-
lowing BRAF inhibitor treatment. This analysis yielded a list of
eight CISs with a P < 0.05 (Fig. 2). Importantly, this list included
Braf, Mitf, and Cdkn2a, all of which have previously been de-
scribed as mediators of resistance to BRAF inhibitors in mela-
noma patients, thus validating the human relevance of our screen
(6, 7, 35–38). In the case of the Mitf locus, 14 out of 15 trans-
poson insertions (6 of which fell into the CIS, Fig. 2) were ori-
entated such that the murine stem cell virus (MSCV) promoter
will drive transcriptional up-regulation of the gene (Fig. S4D).
The remaining candidate genes on the list have not previously
been implicated in resistance to BRAF inhibitor therapy. We
note that by using Fisher’s exact statistics a stringent list of
candidate drug resistance mediators was identified. Further
candidates maybe revealed from our data using alternative
approaches.
Insertional Activation of Truncated Braf Confers Resistance to PLX4720.As
shown in Fig. 2, statistical analysis of PLX4720-naïve and -resistant
tumors revealed a significant enrichment of transposon insertions at
the Braf locus in resistant melanomas (P = 3.43 × 10−08). All nine
insertions within the gene body of Braf in resistant tumors were
oriented such that the MSCV promoter in the transposon will pro-
mote transcriptional activation of Braf, with most producing a trun-
cated isoform that includes the kinase domain of Braf but lacks the
N-terminal regulatory domain (Fig. S5A). Interestingly, five out of
nine insertions were located in intron 9, a hotspot for transposon
insertions in a previously described Braf-driven sarcoma model (26).
We verified the existence of Braf-T2/Onc chimeric transcripts using
primers in exon 10 (n = 4), 2 (n = 2), or 3 (n = 1) of Braf and in the
splice donor of the transposon (Fig. S5B). We next determined
whether transposons were located in the wild-type or V618E mutant
allele of Braf. We analyzed three tumors and found two insertions in
the wild-type allele and one in the mutant BrafV618E allele (Fig. S5C),
suggesting that overexpression of both the wild-type and mutant
kinase domain of Braf is able to confer resistance to PLX4720.
Notably, intron 9 insertions generate a truncated transcript similar to
an alternative splice form of BRAF that confers vemurafenib re-
sistance in human melanoma patients (Fig. S5D) (6), further high-
lighting the clinical relevance of our screen.
The Proto-Oncogene ERas Mediates Melanoma Resistance to PLX4720
Through Activation of the AKT/BAD Pathway. The proto-oncogene
ERas (ES cell-expressed Ras) was also discovered as a candidate
drug resistance gene, with ERas insertions being exclusively
found in PLX4720-resistant tumors and not in PLX4720-naïve
controls (Fig. 2). ERas is a small gene spanning ∼4 kb on the X
chromosome. All four transposon insertions were located in the
first intron (Fig. 3A) and resulted in the generation of chimeric
ERas-transposon transcripts (Fig. S6 A and B).
To validate the role of ERAS in resistance to PLX4720 we
ectopically expressed human ERAS in the BRAFV600E-mutant
melanoma cell lines 451Lu and A375 by retroviral transduction
and assessed survival in response to PLX4720 concentrations
ranging from 0 to 100 μM. ERAS expression reduced sensitivity
to PLX4720 in both cell lines (Fig. 3B and Fig. S6C); indeed, the
concentration required to inhibit cell proliferation by 50% (GI50)
Fig. 2. Candidate resistance genes identified in the BCTSB13 resistant melanomas as CISs. Each gene is annotated by its gene symbol and chromosome of
origin, along with the height of the associated CIS peak with its location and the number of insertions contributing to the CIS. P values are corrected for
multiple testing using the count of all CIS peaks across the genome. The seventh column reports whether a gene was also associated with a CIS in the primary
BCTSB13 melanomas. A Fisher’s exact test was performed to assess the significance of insertion site clusters in primary vs. resistant samples. CISs are sorted by
CIS height.
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was 4.90 vs. 1.31 μM in 451Lu cells and 0.58 vs. 0.20 μM in A375
cells for ERAS-transduced cells vs. controls, respectively.
Previous work has shown that ERas activates the PI3K path-
way, but not the MAPK pathway, when expressed in mouse ES
cells or human cell lines (39, 40). Thus, we examined AKT, ERK,
and MEK phosphorylation in 451Lu cells overexpressing ERAS
and found robust AKT phosphorylation, whereas MAPK activity
was unaffected (Fig. 3C).
Given this result, we then assessed the effect of PLX4720 or
the allosteric AKT inhibitor MK2206 on the PI3K and MAPK
pathways, either alone or in combination, in ERAS-expressing
451Lu melanoma cells and isogenic controls. As shown in
Fig. 3C, PLX4720 treatment efficiently decreased ERK and
MEK phosphorylation regardless of ERAS expression, whereas AKT
phosphorylation was mostly unaffected. In contrast, ERAS-mediated
phosphorylation of AKT was efficiently blunted by MK2206
treatment, and dual PLX4720/MK2206 treatment inhibited both
the MAPK and PI3K signaling pathways (Fig. 3C and Fig. S7).
Accordingly, dual PLX4720/MK2206 treatment negated ERAS-
mediated resistance of 451Lu cells to PLX4720 (Fig. 3B). Im-
portantly, phospho-S6, which has been shown to be a bona fide
predictor of sensitivity to BRAF inhibitors (41), is reduced in
control cells treated with PLX4720, rescued by ERAS expression,
and then decreased to some extent by the combination treatment
(Fig. 3C and Fig. S7). Notably, even though the PI3K pathway is
considered to be the main regulator of S6 phosphorylation
through TORC1 signaling, our data support the role of MAPK
signaling in S6 phosphorylation in BRAFV600E melanoma cells, as
recently reported (41).
Having established that ERAS functions through the PI3K/
AKT pathway in melanoma cells we reasoned that it might
confer resistance to PLX4720 by activating AKT-dependent
survival signals. Therefore, we assessed the effect of PLX4720
treatment of 451Lu cells on members of the Bcl-2 family of
apoptotic proteins, which have been established as important
mediators of melanoma cell survival (42, 43) (Fig. 3D). Impor-
tantly, previous work has suggested that subtle changes in MCL1
levels play a central role in resistance to PLX4720 treatment in
cells with amplified IGF1R, highlighting the key role that Bcl-2
family proteins and their downstream pathways play in resistance
(12). Whereas the levels of the antiapoptotic protein MCL1 were
consistently decreased following PLX4720 treatment, the levels
of the proapoptotic protein BIM were increased. Interestingly,
ERAS overexpression did not alter the expression levels of
MCL1 or BIM in response to PLX4720, suggesting that these
proteins do not play a dominant role in ERAS-mediated re-
sistance. BAD is a proapoptotic protein whose phosphorylation
at S112 and S136 results in its inactivation. Importantly, ERAS
expression led to BAD hyperphosphorylation at both S112 and
S136, suggesting a higher survival threshold (Fig. 3D and Fig.
S7). PLX4720 treatment of ERAS-expressing cells resulted in
decreased BADS112 phosphorylation whereas phospho-BADS136
remained elevated, suggesting a blunted apoptotic response in
these cells. Importantly, the phosphorylation of BADS136 is
mainly PI3K-dependent (44) and was decreased in response to
treatment with the AKT inhibitor MK2206 (Fig. 3D and Fig. S7).
Intriguingly, BADS112 phosphorylation, thought to be largely
MAPK-dependent (45–47), was higher in ERAS-expressing cells,
suggesting cross-talk between the PI3K and MAPK pathways in
the regulation of this site. Nonetheless, phosphorylation of
BADS112 in ERAS-expressing cells was suppressed by PLX4720
treatment, suggesting that BADS136 phosphorylation alone may
be sufficient to mediate resistance to PLX4720. Only with
concomitant inhibition of MAPK and AKT by combinatorial
treatment with PLX4720 and MK2206 did we observe evidence
of dephosphorylation of the BAD protein at both sites (Fig. 3D
and Fig. S7). Accordingly, ERAS expression increased the
survival of PLX4720-treated cells, a phenotype that was ne-
gated by combined treatment with PLX4720 and MK2206 (Fig.
3E). Thus, increased resistance of ERAS-expressing cells to
PLX4720 is mediated, at least in part, through up-regulation of
the PI3K/AKT pathway and phosphorylation/inactivation of the
proapoptotic protein BAD.
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Fig. 3. ERAS expression confers resistance to PLX4720. (A) ERas is among
the top CISs identified in melanomas from mice treated with the BRAF in-
hibitor PLX4720. The structure of the mouse gene (vertical bar, exon) and
the position of transposon insertions are shown. The black arrow indicates
the direction of ERas transcription. Green arrowheads indicate the orienta-
tion of transposon insertion events. The pattern of insertions is consistent
with gene activation. (B) Drug sensitivity was measured for 451Lu (BRAFV600E)
human melanoma cells infected with an empty (control, black line) or with
a human ERAS (red line) expression retroviral vector. A multipoint PLX4720
drug concentration scale (ranging from 0 to 100 μM) was used. Blue line
indicates concomitant treatment with the AKT inhibitor MK2206 (3 μM) for
ERAS cells. Error bars represent SEM between replicates (n = 6). (C) Western
blot analysis showing that ERas induces phosphorylation of AKT, which can be
reversed by treatment with the AKT inhibitor MK2206. Control and ERAS-
expressing 451Lu cells were assayed after 18 h of treatment with DMSO (un-
treated control) or 1 μM PLX4720 or 3 μM MK2206 or the combination of
them. HSP90 protein levels were used as loading control. (D) BAD hyper-
phosphorylation induced by ERAS expression in 451Lu cells is resolved by
concomitant treatment with PLX4720 and MK2206. The experiment was per-
formed as in B. (E) Combinatorial BRAF and AKT inhibition enhances apoptotic
response in ERAS expressing cells. Control and ERAS 451Lu cells were treated
with PLX4720 (3 μM), MK2206 (4 μM), or a combination of them (PLX + MK)
for 72 h. Cells were then stained with Annexin-V and analyzed by flow
cytometry. Mean and SEM of three independent experiments are shown.
Significance was assessed using the Student’s two-tailed t test. *P < 0.05; **P <
0.01; ns, not significant.
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ABT-263 is a BAD-like BH3 mimetic compound that like
BAD binds with high affinity to Bcl-xL, Bcl-2, and Bcl-w (48).
In accordance with the above data, we found a statistically
significant association between the basal expression of ERAS and the
level of sensitivity to ABT-263 in the panel of 1,000 human cancer
cell lines analyzed by the Genomics of Drug Sensitivity in Cancer
(49) project (Materials and Methods). When considering subgroups
of cell lines falling within extreme quantiles of ERAS basal expres-
sion (5% and 10%) we observed a statistically significant difference
in response to ABT-263, in terms of variation of half-maximal in-
hibitory concentration (P = 0.009 and 0.0008; Fig. S8). In both cases,
cell lines with high expression levels of ERAS were significantly
more sensitive to ABT-263 compared with low ERAS-expressing
cells (Fig. S8 and Dataset S1). We also performed the same
analysis for the pan-AKT inhibitor MK2206 but no significant
association was observed.
The AKT/BAD Pathway Contributes to HGF-Mediated BRAF Inhibitor
Resistance. A correlation between stromal production of HGF in
patients with BRAF mutant melanoma and resistance to BRAF
inhibitors was recently reported. This is due to concomitant
reactivation of both MAPK and PI3K pathways in melanoma
cells expressing the HGF receptor MET (13, 14). Because HGF
is known to regulate cell survival through PI3K-mediated phos-
phorylation/inhibition of BAD (50, 51), we asked whether HGF
causes resistance to vemurafenib through the regulation of BAD.
Therefore, we took three of the MET-expressing melanoma cell
lines previously used in Straussman et al. (14) (G-361, SK-
MEL-5, and SK-MEL-28) and determined the levels of BAD
phosphorylation at S112 and S136 in response to PLX4720 with
the addition of HGF under conditions previously shown to elicit
resistance, and without HGF as a control. As previously re-
ported, HGF treatment activated the MET receptor and reac-
tivated both MAPK and PI3K pathways. BAD remained hyper-
phosphorylated following PLX4720 treatment in the context of
HGF, compared with cells treated with the BRAF inhibitor alone
(Fig. 4A and Fig. S7). The extent of the induction of BAD
phosphorylation by HGF in PLX4720-treated cells seems to cor-
relate with the level of phospho-S6, which is high in G-361 and
SK-MEL-5 cells but lower in SK-MEL-28 cells. Also, because
expression levels of the MET receptor were generally lower in SK-
MEL-28 cells (Fig. 4A), this result is in accordance with the pre-
vious observation that the extent of HGF-induced drug resistance
directly correlates with MET expression (13).
As a further proof of the key role of the Bcl-2 family in HGF-
induced resistance to PLX4720 we asked whether resistance could
be reverted by concomitant treatment with the BAD-like BH3
mimetic compound ABT-737. We measured growth of G-361, SK-
MEL-5, and SK-MEL-28 cells untreated or treated with PLX4720,
HGF, ABT-737, or with combinations of these compounds (Fig.
4B) and reveal that cells treated with HGF, PLX4720, and ABT-
737 are growth-inhibited compared with HGF, PLX4720-treated
cells. Thus, BAD inhibition may contribute to HGF-mediated
PLX4720 resistance in melanoma.
Discussion
Here we deployed the Sleeping Beauty transposon system in
a mouse model of melanoma to identify genes that accelerate
oncogenic Braf-induced melanoma development, and also
mediators of resistance to the BRAF inhibitor PLX4720. We
identified 56 candidate loci that may promote melanoma for-
mation in BrafV618E mice, including known tumor suppressors
such as Cdkn2a and Pten. Moreover, we found eight candidate
loci conferring resistance to PLX4720 treatment. Interestingly,
both lists contained Mitf, which is a well-known melanoma on-
cogene amplified in ∼10% of primary and ∼20% of metastatic
melanomas (35, 52, 53) and has been described as a mediator of
drug resistance in melanoma (35–37, 54, 55).
We focused our attention on two of the candidate resistance
genes identified in our in vivo screen: Braf and ERas. The
identification of Braf in PLX4720-resistant, but not in PLX4720-
naïve, tumors underscores the clinical relevance of our screen,
because expression of alternative BRAF isoforms is associated
with vemurafenib resistance in human melanoma patients (6).
Interestingly, transposon insertion into the murine Braf gene
generated truncated Braf transcripts (Fig. S5) that functionally
resembled the alternative isoforms found in BRAF inhibitor-
resistant human tumors. We observed transposon insertions in
both the wild-type and BrafV618E alleles, suggesting that over-
expression of wild-type mouse Braf, which is as much as 10 times
less sensitive to PLX4720, is sufficient to sustain tumor growth in
the presence of BRAF inhibitor treatment. In contrast, selective
alteration of the oncogenic BRAFV600E allele is found in human
melanomas with acquired BRAF inhibitor resistance.
The ERas (ES cell-expressed Ras) proto-oncogene, another
gene identified from our screen, is a recently discovered member
of the Ras family, which encodes a protein of 227 aa sharing
43%, 46%, and 47% identity with HRAS, NRAS, and KRAS,
respectively. It was first identified as a potent oncogene in mu-
rine ES cells because of its ability to promote constitutive acti-
vation of the PI3K pathway (39). More recently, human ERAS
has been proposed to play a role in cancers of the gastrointes-
tinal tract (40, 56), and in vitro studies have suggested a role in
the resistance of cell lines to chemotherapeutics (57, 58).
Remarkably, we identified four independent tumors with
insertions in the ERas gene, despite its very small size (∼4 kb)
(P = 4.9 × 10−12). We show that overexpression of ERAS causes
hyperactivation of AKT. Importantly, the PI3K/AKT pathway is
a major regulator of apoptotic cell death and cell survival. The
proapoptotic protein BAD has been shown to be inactivated by
AKT-mediated phosphorylation at S136 (44). Another site of
BAD phosphorylation is serine 112, which is regulated by MAPK
signaling (45–47), and a full apoptotic response is only achieved
when both BADS112 and BADS136 residues are dephos-
phorylated through the suppression of both pathways (59). Im-
portantly, others have proposed a role for members of the Bcl-2
family in resistance to BRAF inhibitor treatment. Villanueva
et al. (12) identified MCL1 as a prosurvival factor that confers
resistance to BRAF inhibition in IGF1R-overexpressing cells,
whereas Paraiso et al. (15) found that intrinsic resistance to
PLX4720 in PTEN-mutant cells was the result of suppression of
BIM expression resulting in a blunted apoptotic response. Here
we show that ERAS confers PLX4720 resistance by promoting the
hyperphosphorylation of BADS112 and BADS136, thus counteracting
the inhibition of the MAPK pathway and dephosphorylation of
BADS112 alone (Figs. 3 C and D and 4C). Consequently, ERAS-
expressing cells have a higher threshold for the induction of
apoptosis and are less sensitive to PLX4720 treatment. Because
this phenotype can be reverted using the AKT inhibitor MK2206
(Fig. 3 D and E) our data suggest a combinatorial approach to
therapy in BRAF inhibitor-resistant melanomas that harbor
hyperactivation of AKT. At this time a link between ERAS ex-
pression, BAD phosphorylation, and resistance to BRAF inhib-
itors is yet to be examined in patients and will require the
comparison of expression/phosphoproteome data from large
panels of melanomas sensitive and resistant to therapy once such
data become available.
Therefore, to determine the relevance of our findings in humans,
we sought to investigate the mechanism by which HGF signaling
induces resistance to BRAF inhibition, because HGF is a known
regulator of BAD (50, 51). Similar to our observations in the
mouse, we determined that activation of HGF signaling inactivates
BAD by preventing its full dephosphorylation in human melanoma
cell lines. Furthermore, we determined that treatment of cells with
the BAD-like BH3 mimetic compound ABT-737 partially rescues
the resistance phenotype-induced by HGF, supporting the role of
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Fig. 4. HGF signaling confers resistance to PLX4720 associatedwith inactivation of BAD and sensitivity to ABT-737/PLX4720 combination. (A) Western blot analysis of
the impact ofHGF treatment±PLX4720 on thephosphorylation levels ofMET, ERK,AKT, BAD, and S6. G-361, SK-MEL-5, and SK-MEL-28melanomacell lines (BRAFV600E
mutant) were assayed after 24 h of treatment with 2 μMPLX4720 or 100 ng/mL HGF or the combination of both. β-ACTIN protein levels were used as loading control.
(B) Growth curves ofG-361, SK-MEL-5, and SK-MEL-28 cells untreated or treatedwith PLX4720, HGF, ABT-737, or combinations of them. Cellswere seededonday 0 and
treatedwith drugs at day 1 and cellular proliferationwas assessedbyMTS assay at days 0, 2, 4, and 6.ABT-737was used at the IC20 concentration as determined for each
specific cell line. Compound concentrations used forG-361: 2 μMPLX-4720, 100 ng/mLHGF, and 3 μMABT-737; for SK-MEL-5: 4 μMPLX-4720, 100 ng/mLHGF, and 2 μM
ABT-737; for SK-MEL-28: 1 μMPLX-4720, 100 ng/mLHGF, and 5 μMABT-737.Mean and SDof replicates (n= 6) is shown. Asterisks indicate the result of the Student two-
tailed t test comparing cells treatedwith PLX4720+HGF and cells treatedwith PLX4720+HGF+ABT-737 at day 6 (**P< 0.01). (C) Schematicmodel showing regulation
of BAD phosphorylation inmelanoma. Hyperphosphorylation of BAD at S112 and S136 sites through activity ofMAPK and ERAS/PI3K pathways determine cell survival
(Top), whereas combined inhibition of these pathways by BRAF inhibitor PLX4720 and AKT inhibitor MK2206 causes BAD dephosphorylation and induction of ap-
optosis (Middle). HGF signaling is able to induce phosphorylation of BAD also in the presence of BRAF inhibition favoring cell survival and drug resistance (Bottom).
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BAD and the Bcl-2 family in this mechanism of resistance. Be-
cause HGF-dependent resistance has been shown to operate in
patients where stromal expression of HGF can be detected, our
experiments suggest that regulation of the activity of BAD is
relevant in determining the response of melanomas to BRAF
inhibition. It should be noted that because several components
of the Bcl-2 family of proteins have been linked to the response
of cells to ABT-263/ABT-737, in particular MCL-1, BAX, and
BIM (60, 61), a complex interplay between these proteins and
BAD could mediate the overall resistance phenotype in response
to HGF.
Our work represents the first example, to our knowledge, of
the use of transposon-mediated mutagenesis to find mechanisms
of cancer drug resistance. As illustrated here this approach has
the potential to identify novel genes and mechanisms and may be
particularly useful for revealing mediators of resistance to im-
mune therapies and biotherapeutics in in vivo model systems.
Materials and Methods
Generation of the LSL-BrafV618E Allele. See SI Materials and Methods.
Mice. The following alleles were used to generate the BC mouse model of
melanoma: LSL-BrafV618E (Braftm1Tuv), Tyr-CreERT2 [Tg(Tyr-cre/ERT2)13Bos]
(22). BC mice were intercrossed with the following strain to generate the
BCTSB13 mouse: T2/Onc (TgTn(sb-T2/Onc)68Dla) (26), Rosa26-LSL-SB13 (Gt
(ROSA)26Sortm1(sb13)Tuv) (28). Melanocyte-specific Cre-mediated activation of
the Braf V618E mutant and of the SB13 transposase was obtained by topical
administration of a 25 mg/mL solution of 4-OHT (70% Z-isomer; Sigma) in
DMSO. The solution was applied with a paintbrush on the trunk, flanks, ears,
and tail of 3-wk-old mice for two consecutive days. Size of arising melano-
mas was determined twice a week by caliper measurements of tumor length
and width and volume was calculated using the following formula:
Volume= ðπ=6ÞðabbÞ,
where b is the shorter of the two measurements.
Tumor weight was estimated by assuming that 1 cm3 = 1 g.
In accordance with U.K. Home Office Regulations mice were killed when
the estimated external tumor weight was maximum 10%of the body weight.
To prepare plasma samples for PK analysis of PLX4720, the mice were
anesthetized with isoflurane and terminal blood samples were collected by
cardiac puncture immediately before culling in tubes containing lithium
heparin. After centrifugation of the blood samples plasma was then
separated and frozen before the analysis. Mice were housed at a 12-h light/
12-h dark cycle. All work was performed in accordance with Cancer Research
UK and Wellcome Trust Sanger Institutes’ Animal Welfare and Ethical Review
Body (AWERB). All procedures were approved by the Home Office (UK).
CIS Analysis. Splinkerette PCRs were performed from 278 naïve and 53
PLX4720-resistant BCTSB13 melanomas as described previously (62, 63).
Reads from sequenced tumors were mapped to the mouse genome assembly
NCBI m37 and merged together to identify SB insertion sites. Redundant
sequences, as well as insertions in the T2/Onc donor concatamer resident
chromosome (chromosome 1), were removed. Analysis of CISs was per-
formed as previously described (62). For the statistical analysis, non-
redundant insertion sites (40,395 from naïve and 11,070 from PLX-resistant
tumors) were used to identify CISs using a GKC framework (30).
Multiple kernel scales were used in the GKC framework (widths of 15,000,
30,000, 50,000, 75,000, 125,000, and 250,000 nucleotides). CISs predicted
across multiple scales and overlapping in their genomic locations were
clustered together, such that the CIS with the smallest genomic “footprint”
was reported as the representative CIS. For highly significant CISs with
narrow spatial distributions of insertion sites the 15,000 kernel is typically
the scale on which CISs are identified.
Comparison of Primary and Resistant CISs. A gene-centric approach was used
to assess the significance of insertion-site clusters in primary vs. resistant
samples. The genomic spans of CISs were retrieved for both the primary and
resistant samples. Overlapping CISs were merged into a single genomic span.
Each spanwas then checked for the presence of a translatable gene, or genes,
within the region using version 67 of the EnsEMBLmouse genome annotation
database. For each overlapping gene the start and end coordinates of every
potential transcript were determined.
Using the coordinates of the transcripts, counts weremade of the insertion
sites contained within these regions from the primary and resistant samples.
Insertions were counted on the sample level (i.e., a sample could have
multiple insertions within the span of transcript but the sample was only
counted once). For each transcript the following single-tailed Fisher exact test
was performed: number of resistant samples in transcript per number of
primary samples in transcript and number of resistant samples not in tran-
script per number of primary samples not in transcript.
Whole-Exome Sequencing of Mouse Tumors Resistant to PLX4720.Whole-exome
sequencing was performed using the Agilent SureSelect Mouse All Exon kit.
Captured material was indexed and sequenced on the Illumina GAII and
HiSeq2000 platforms at the Wellcome Trust Sanger Institute. Successfully
sequenced readswere then aligned to themouse reference genome (GRCm38)
before base quality score recalibration and realignment around InDels. We
used the Cake somatic variants detection pipeline as described previously (64).
Variant calls were filtered for quality and depth and known germ-line var-
iants were removed (65).
Detection of ERas-T2/Onc and Braf-T2/Onc Fusion mRNA by RT-PCR in SB
Tumors. Mouse tissue samples were immediately placed in RNAlater solu-
tion (Qiagen) and stored for at least 24 h at 4 °C and then snap-frozen until
they were processed. Total RNA was then isolated from frozen SB tumors by
use of the Qiagen TissueLyser and Qiagen RNeasy Mini kit according to
manufacturer instructions, and contaminating DNA was removed by treat-
ment with RNase-Free DNase Set (Qiagen). One microgram of RNA
was reverse-transcribed into cDNA using the High Capacity RNA-to-cDNA kit
(Applied Biosystems). RT-PCR was carried out with a nested PCR approach
using primers in the coding sequence of the mouse ERas or Braf genes and
the Foxf2 splice donor sequence of the T2/Onc transposon cassette. cDNA was
used as a template in the first round of PCR, and the product was then used
for the second round of nested PCR. PCR products were cloned into pCR-Blunt
II-TOPO vector (Life Technologies) and positives clones were sequenced. PCR
primer sequences are available upon request.
PLX4720 PK Bioanalysis. Plasma and tissue concentrations of drugs were de-
termined at Integrated Analytical Solutions by extracting the sample
homogenates with acetonitrile (containing internal standards), diluting with
5× volume of 0.2% formic acid, and analyzing by liquid chromatography-
tandem mass spectrometry.
PLX4720 Drug Chow Preparation. PLX4720 was provided by Plexxikon and was
prepared as a drug chow at Research Diets Inc. For preparation of each ki-
logram of rodent chow, 417mg of PLX4720 was comixed with ingredients for
the control AIN-76A purified rodent diet. PLX4720 and control chows were
irradiated after preparation to control growth of microorganisms. With
typical consumption the expected drug dose delivered is ∼75 mg·kg−1·d−1.
Cell Culture. BRAFV600E mutant human melanoma cell lines were STR-vali-
dated and mycoplasma-tested. The 451Lu and A375 cells were cultured in
DMEM supplemented with 10% FCS, whereas G-361, SK-MEL-5, and SK-MEL-
28 cells were cultured in RPMI supplemented with 10% FCS. BRAF inhibitor
PLX4720 (Plexxikon), the AKT inhibitor MK2206, and the BAD-like BH3 mi-
metic compound ABT-737 (Selleckchem) were dissolved in DMSO and used as
indicated. HGF (Sigma) was dissolved in PBS containing 0.2% BSA, sterile-
filtered, and used at 100 ng/mL.
To generate mouse embryo fibroblasts (MEFs) E13.5-E14.5 embryos were
eviscerated, minced in 0.25% trypsin, and passed through pipettes to gen-
erate single-cell suspensions. MEFs were cultured in DMEM supplemented
with 10% (vol/vol) FCS. MEFs were infected with adenoviruses containing Cre
or Flpe recombinases or empty control purchased from the University of
Iowa Gene Transfer Vector Core facility.
Cell Viability and Apoptosis Assays. For cell viability assay cells were seeded
into 96-well plates (1,000 cells per well for 451Lu line or 500 cells per well for
A375 line). Twenty-four hours later cells were treated with increasing con-
centration of PLX4720 (0.01–100 μM) with or without the presence of 3 μM
MK2206 and incubated for 4 d. Six replicates were performed for each cell
line and drug combination. At the end of the incubation cell viability was
measured using the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega) according to manufacturer instructions. Absorbance read-
ings were subtracted from the value of blank wells and the reduction in cell
growth was calculated as a percentage of absorbance in the absence of any
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drug. Data were analyzed using a nonlinear regression curve fit with a sig-
moidal dose response using GraphPad Prism 6 software.
For apoptosis analysis melanoma cells were treated with 3 μM PLX4720
and/or 4 μM MK2206 for 72 h. Cells were then detached with Accutase
(Millipore) and stained with Annexin V Alexa Fluor 488 Conjugate and
SYTOX AADvanced Dead Cell Stain Kit (Life Technologies) according to
manufacturer instructions. Samples were subsequently analyzed with an
LSRFortessa (BD) apparatus.
Correlation Between ERAS Basal Expression and Drug Response in Human
Cancer Cell Lines. To evaluate the extent of correlation between the basal
expression of ERAS and response to drug treatment in human cancer cell
lines we made use of a large-scale drug screening dataset from the Genomics
of Drug Sensitivity in Cancer project (49). In this study a large collection of
∼1,000 genomically characterized human cancer cell lines has been screened
for reduction in viability after 72 h of treatment with ∼140 different com-
pounds at nine different concentrations. From this dataset we extracted
IC50 (i.e., half-maximal inhibitory concentration) values. Additionally, we
obtained the basal expression profiles for the panel of cell lines in the same
study. From the raw CEL files we computed normalized gene expression
intensities by using the robust multiarray average method (66).
Finally, we further normalized the resulting expression datasets gene-
wisely as follows.We first estimated the probability distribution Pg describing
the expression of a given gene g across the cell lines by using a non-
parametric Gaussian kernel estimator. Then we assigned to each expression
values xg,l (of gene g in cell line l) a normalized expression score equal to
zg,l = log
 
CDFg

xg,l

1−CDFg

xg,l

!
,
where CDFgðxÞ is the cumulative distribution of gene g at x:
Finally, for the drug association test, we considered two groups of cell
lines, the first corresponding to samples falling within the nth percentile of
ERAS normalized expression and the second corresponding to samples fall-
ing over the (100 − n)th percentile of ERAS normalized expression (for n = 5
and 10). Then we performed an unpaired Welch’s t test considering as de-
pendent variable the IC50 value of the drug under consideration across the
cell lines in the two defined quantiles and the resulting groups as factors.
Senescence-Associated β-Gal Staining. LSL-BrafV618E MEFs were fixed in 2%
formaldehyde/0.2% glutaraldehyde in PBS for 5 min and stained in staining
solution (citric acid/phosphate buffer pH 6.0, 150 mM NaCl, 2 mM MgCl,
5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mg·mL−1
X-gal) overnight at 37 °C. Fields of at least 50 cells were counted,
in triplicate.
Plasmids and Retroviral Infections. The human ERAS full-length cDNA was
purchased as a TrueORF (OriGene) and sequence-verified. It was then subcloned
into a pBabe Puro retroviral vector. To prepare retrovirus, packaging Phoenix
cells were seeded and transfected 24 h later using the ProFection Mammalian
Transfection System Calcium Phosphate kit (Promega). Human melanoma tar-
get cells were infected with retroviruses produced in the packaging cells (24
and 48 h after transfection) in the presence of 8 μg/mL Polybrene (Millipore)
and were selected with 1 μg/mL Puromycin (Life Technologies).
Western Blotting. Cells were washed three times in cold PBS and protein
lysates were obtained by the use of RIPA buffer with protease and phos-
phatase inhibitors (Cell Signaling). Equivalent amounts of protein were re-
solved in 4–12% gradient SDS/PAGE gels (Life Technologies), transferred to
Immobilon-P Transfer Membranes (Millipore), and incubated with the fol-
lowing primary antibodies: HSP90 (4875, lot number 3), phospho-ERK1/
2T202/Y204 (4370, lot number 12), ERK1/2 (4695, lot number 8), phospho-
AKTS473 (4060, lot number 16), AKT (9272, lot number 24), phospho-MEK1/
2S221 (2338, lot number 6), MEK1/2 (9122, lot number 7), phospho-S6S235/S236
(2211, lot number 5), MCL1 (4572, lot number 4), BIM (2819, lot number 6),
phospho-BADS112 (5284, lot number 3), phospho-BADS136 (5286, lot number
4), phospho-METTyr1234/1235 (3077, lot number 6), and MET (8198, lot number
4) from Cell Signaling; Actin (sc-1615, lot number I1508) and BAD (sc-7869, lot
number H1810) from Santa Cruz Biotechnology; and ERAS (AP1470a, lot
number SHO71102T) from Abgent. Membranes were then incubated with
secondary horseradish peroxidase antibodies (Jackson ImmunoResearch) and
developed by use of the ECL detection system (GE Healthcare). Western blot
signals have been quantified by scanning densitometry with ImageJ software.
PCR and Southern Blot. PCR and Southern blot analyses were carried out in
accordance with standard techniques.
Histology and Immunohistochemistry. Tissues were fixed in 10% neutral buff-
ered formalin for 24 h and transferred to 70% ethanol. Tissues were embedded
in paraffin, and 3- to 5-μm sections were processed for hematoxylin–eosin
staining and immunohistochemistry.
Antigen retrieval was heat-mediated using citrate buffer at pH 6.0. En-
dogenous peroxidases were blocked with 3% hydrogen peroxide, followed
by serum and avidin–biotin blocking. Primary antibodies were incubated
overnight at 4 °C. Secondary antibodies were incubated at room tempera-
ture for 30 min. Antigens were developed with Vectastain ABC reagents and
peroxidase substrate DAB kit (Vector Labs). Primary antibodies used were
anti-S100 (1:1,000; Dako) and MITF (1:50; Santa Cruz). Slides were counter-
stained with hematoxylin.
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